A minimally invasive procedure using electrical pulses in the small intestine shows promise in significantly improving type 2 diabetes, with benefits rivaling gastric bypass surgery.
April’s FDA approvals feature first-in-class therapies, targeted biologics, expanded indications, and innovative delivery systems across allergy, endocrinology, rheumatology, oncology, infectious diseases, and more.